Cancer de Primitif Inconnu (CAPI)
|
|
- Clare Parsons
- 8 years ago
- Views:
Transcription
1 Cancer de Primitif Inconnu (CAPI) Cancer of Unknown Primary origin (CUP) Vincent Berry (Lille) 23/01/2015 Dirigé par le Dr PENEL
2 Définitions Définitions Epidémiologie Anatomo pathologie Explorations Pronostic Traitements (2) Conclusions
3 Définitions Cancer Métastatique Localisation initiale non retrouvée Après un bilan standardisé
4 Définitions Varadhachary GR. Carcinoma of unknown primary origin. Gastrointest Cancer Res Nov;1(6): Tumeur primitive Cachée parmi les métastases Trop petite Dormance Mauvaise vascularisation Destruction par le système immunitaire Métastatique Agressive et/ou évoluée Modification d expression/séquences Ras (92%), Bcl-2 (40%), Her-2 (11%), and p53 (26% 53%)
5 Un concept, des pathologies Briasoulis E, Pavlidis N. Cancer of unknown primary origin. Oncologist 1997; 2:
6 Un concept, des pathologies Autopsies de 302 patients Identification du primitif : 84 % patient vivant : 27% à l autopsie : 57% Pancréas : 26.5% Poumons : 17.2% Reins : 4.6% Colo rectal : 3.6% Le Chevalier T, Cvitkovic E, Caille P et al. Early metastatic cancer of unknown primary origin at presentation: a clinical study of 302 consecutive autopsied patients. Arch Intern Med 1988;148: Pas d identification : 16%.
7 Epidémiologie Définitions Epidémiologie Anatomo pathologie Explorations Pronostic Traitements (2) Conclusions
8 Complexe à obtenir «Autres tumeurs» Epidémiologie Briasoulis E, Pavlidis N. Cancer of Unknown Primary Origin. Oncologist. 1997;2(3): Incidence estimée : 3 à 5% de tous les cancers 7-12/an pour Sex ratio Age médian 59 ans
9
10 Facteurs de risque Kaaks R, Sookthai D, Hemminki K, et al. Risk factors for cancers of unknown primary site: Results from the prospective EPIC cohort. Int J Cancer Nov 15;135(10): Table 2. Hazard ratios and 95% confidence intervals for CUP in relation to smoking, alcohol consumption, levels of education and anthropometric indices of obesity
11 Anatomo pathologie Définitions Epidémiologie Anatomo pathologie Explorations Pronostic Traitements (2) Conclusions
12 Anatomie pathologie Eliminer : Lymphomes Mélanomes Sarcomes Confirmer : Carcinome Affiner : Carcinome épidermoïde Carcinome indifférencié Adénocarcinome
13 Dolled-Filhart MP, Rimm DL. Gene expression array analysis to determine tissue of origin of carcinoma of unknown primary: cutting edge or already obsolete? Cancer Cytopathol Mar;121(3):
14 Varadhachary GR. Carcinoma of unknown primary origin. Gastrointest Cancer Res Nov;1(6):
15 Etudes de l expression génique Dolled-Filhart MP, Rimm DL. Gene expression array analysis to determine tissue of origin of carcinoma of unknown primary: cutting edge or already obsolete? Cancer Cytopathol Mar;121(3):
16 Explorations Définitions Epidémiologie Anatomo pathologie Explorations Pronostic Traitements (2) Conclusions
17 Fizazi K, Greco FA, Pavlidis N, Pentheroudakis G; ESMO Guidelines Working Group. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22 Suppl 6:vi64-8
18 Fizazi K, Greco FA, Pavlidis N, Pentheroudakis G; ESMO Guidelines Working Group. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22 Suppl 6:vi64-8
19 Fizazi K, Greco FA, Pavlidis N, Pentheroudakis G; ESMO Guidelines Working Group. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22 Suppl 6:vi64-8
20 TEP Møller AKH, Loft A, Berthelsen AK, et al. A prospective comparison of 18F-FDG PET/CT and CT as diagnostic tools to identify the primary tumor site in patients with extracervical carcinoma of unknown primary site. Oncologist. 2012;17(9):
21 Fibroscopies digestives Yield of esophagogastroduodenoscopy and colonoscopy in cancer of unknown primary. Usmani MT, Bin Khalid A, Ali Shah SH, et al. Pak J Med Sci Apr;29(2):523-7
22 Evaluation pronostique Définitions Epidémiologie Anatomo pathologie Exploration Pronostic Traitements (2) Conclusions
23 Pavlidis N. Optimal therapeutic management of patients with distinct clinicopathological cancer of unknown primary subsets. Ann Oncol Sep;23 Suppl 10:x282 5.
24 Survie médiane 36 mois Pavlidis N. Optimal therapeutic management of patients with distinct clinicopathological cancer of unknown primary subsets. Ann Oncol Sep;23 Suppl 10:x Curable?? 12mois Curable???? 15mois 20mois NC Curable????
25 Survie médiane Pavlidis N. Optimal therapeutic management of patients with distinct clinicopathological cancer of unknown primary subsets. Ann Oncol Sep;23 Suppl 10:x mois??
26 Amela EY, Lauridant-Philippin G, Cousin S, et al. Management of unfavourable carcinoma of unknown primary site: Synthesis of recent literature. Critical Reviews in Oncology/ Hematology Nov;84(2):
27 Traitements (1) CUP de bon pronostic Définitions Epidémiologie Anatomo pathologie Explorations Pronostic Traitements (2) Conclusions
28 Fizazi K, Greco FA, Pavlidis N, Pentheroudakis G; ESMO Guidelines Working Group. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22 Suppl 6:vi64-8
29 Traitements (2) CUP de mauvais pronostic Définitions Epidémiologie Anatomo pathologie Explorations Pronostic Traitements (2) Conclusions
30 GEFCAPI 01 Culine S, Lortholary A, Voigt J-J, et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol Sep 15;21(18):
31 GEFCAPI 02 M. Gross-Goupil a,, A. Fourcade a, E. Blot et al. Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: Results of the randomised GEFCAPI 02 trial. Eur J Cancer 2012 Mar;48(5):721-7
32 GEFCAPI 02 M. Gross-Goupil a,, A. Fourcade a, E. Blot et al. Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: Results of the randomised GEFCAPI 02 trial. Eur J Cancer 2012 Mar;48(5):721-7
33 Huebner G, Link H, Kohne CH, et al. Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. British Journal of Cancer Jan 13;100(1):44 9.
34 Huebner G, Link H, Kohne CH, et al. Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. British Journal of Cancer Jan 13;100(1):44 9.
35 Briasoulis E, Fountzilas G, Bamias A, et al. Multicenter phase-ii trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poorprognosis cancer of unknown primary: a hellenic cooperative oncology group study. Cancer Chemotherapy and Pharmacology Jul;62(2):
36 Golfinopoulos V, Pentheroudakis G, Salanti G, et al. Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: Multiple-treatments meta-analysis. Cancer Treatment Reviews Nov;35(7):570 3.
37 Golfinopoulos V, Pentheroudakis G, Salanti G, et al. Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: Multiple-treatments meta-analysis. Cancer Treatment Reviews Nov;35(7):570 3.
38 Lee J, Hahn S, Kim D-W, et al. Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis. Br J Cancer Jan 15;108(1):39 48.
39 2 e ligne Ono M, Ando M, Yonemori K, et al. Second-line chemotherapy in patients with primary unknown cancer. Journal of Cancer Research and Clinical Oncology Aug;137(8):
40 2 e ligne Ono M, Ando M, Yonemori K, et al. Second-line chemotherapy in patients with primary unknown cancer. Journal of Cancer Research and Clinical Oncology Aug;137(8):
41 Conclusions Définitions Epidémiologie Anatomo pathologie Exploration Pronostic Traitements (2) Conclusions
42 Fizazi K, Greco FA, Pavlidis N, Pentheroudakis G; ESMO Guidelines Working Group. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22 Suppl 6:vi64-8
43 Ducoulombier A., Adenis A., Robin Y- M., Penel N. Cancer de primitif inconnu : les formes cliniques à expression digestive. Hépato-Gastro & Oncologie Digestive 2012 ; 9 : 730-6
44 Merci! Définitions Epidémiologie Anatomo pathologie Exploration Pronostic Traitements (2) Conclusions
45
46 Cancer de Primitif Inconnu (CAPI) Cancer of Unknown Primary origin (CUP) Vincent Berry (Lille) 23/01/2015 Dirigé par le Dr PENEL
47
48 Kaaks R, Sookthai D, Hemminki K, et al. Risk factors for cancers of unknown primary site: Results from the prospective EPIC cohort. Int J Cancer Nov 15;135(10):
49 Kaaks R, Sookthai D, Hemminki K, et al. Risk factors for cancers of unknown primary site: Results from the prospective EPIC cohort. Int J Cancer Nov 15;135(10):
50 Amela EY, Lauridant-Philippin G, Cousin S, et al. Management of unfavourable carcinoma of unknown primary site: Synthesis of recent literature. Critical Reviews in Oncology/ Hematology Nov;84(2):
51 Dolled-Filhart MP, Rimm DL. Gene expression array analysis to determine tissue of origin of carcinoma of unknown primary: cutting edge or already obsolete? Cancer Cytopathol Mar;121(3):
Metastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab
COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Carboplatin INDICATION: Metastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab COMPENDIA TRANSPARENCY
More informationEVALUATION/PRIORITIZATION CRITERIA: C, L, R, S *to meet requirement 1
COMPENDIA TRANSPARENCY TRACKING FORM DATE: MAY 2015 PACKET: 111 DRUG: INDICATION: Vinorelbine Tartrate Malignant pleural mesothelioma COMPENDIA TRANSPARENCY REQUIREMENTS 1 Provide criteria used to evaluate/prioritize
More informationSur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue)
Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue) Professeur Jean Trédaniel Unité de cancérologie thoracique Hôpital Saint-Louis Comparison of Four
More informationDocteur Oswald VAN CUTSEM Pneumologue Chef de Service
Docteur Oswald VAN CUTSEM Pneumologue Chef de Service Contacts secrétariat planning : 081. 20 96 61 secrétariat consultations : 081. 20 94 61 Diplômes : Doctorat UCL 1983 Diplôme de spécialiste en pneumologie
More informationAdjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015
Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3
More informationEmerging Drug List GEFITINIB
Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:
More informationNCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10
Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage
More informationMaintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
More informationIs the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study
Turkish Journal of Cancer Volume 34, No.1, 2004 19 Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study MUSTAFA ÖZDO AN, MUSTAFA SAMUR, HAKAN BOZCUK, ERKAN ÇOBAN,
More informationNon-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin
COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Docetaxel INDICATION: Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin COMPENDIA TRANSPARENCY REQUIREMENTS 1 Provide
More informationCytotoxic Therapy in Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Version 2002: von Minckwitz Versions
More informationavailable at www.sciencedirect.com journal homepage: www.elsevierhealth.com/journals/ctrv
Cancer Treatment Reviews (2008) 34, 693 700 available at www.sciencedirect.com journal homepage: www.elsevierhealth.com/journals/ctrv TUMOUR REVIEW Liver metastases from cancer of unknown primary (CUPL):
More informationWhat is the reference cytotoxic regimen in advanced gastric cancer?
What is the reference cytotoxic regimen in advanced gastric cancer? Florian Lordick Professor of Oncology Director of the University Cancer Center Leipzig (UCCL) Germany What we know from clinical research.
More informationNational Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007
Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.
More informationSummary ID# 13095. Clinical Study Summary: Study H3E-EW-B012
Page 1 Summary ID# 13095 Clinical Study Summary: Study H3E-EW-B012 First-line Treatment of Non-Small Cell Lung Cancer under Routine Conditions: Observational Study on Overall Survival Date summary electronically
More informationGastric or gastroesophageal junction cancer, advanced, as first-line therapy in combination with fluoropyrimidine-based
COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Cetuximab INDICATION: chemotherapy Gastric or gastroesophageal junction cancer, advanced, as first-line therapy in combination with fluoropyrimidine-based COMPENDIA
More informationmicrorna Signatures in Cancer E. ROBERT WASSMAN, MD, FAAP, FACMG CHIEF MEDICAL OFFICER, ROSETTA GENOMICS
microrna Signatures in Cancer E. ROBERT WASSMAN, MD, FAAP, FACMG CHIEF MEDICAL OFFICER, ROSETTA GENOMICS 1st International Congress on Controversies in Personalized Oncology (CONPO) BARCELONA, SPAIN MARCH
More informationDrug/Drug Combination: Bevacizumab in combination with chemotherapy
AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy
More informationAdiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka
Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Neoadiuvant and adiuvant therapy for advanced gastric cancer Franco Roviello, IT Neoadjuvant and adjuvant therapy for advanced
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationCancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationFuture Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center
Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.
More informationREPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group
REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory
More informationThrombose associée au cancer. Prévention et traitement. Guy Meyer Université Paris Descartes Hopital Europeen Georges Pompidou, Paris, France
Thrombose associée au cancer Prévention et traitement Guy Meyer Université Paris Descartes Hopital Europeen Georges Pompidou, Paris, France Conflits d intérêt G Meyer Investigateur: Bayer, Daichi-Sankyo,
More informationAT&T Global Network Client for Windows Product Support Matrix January 29, 2015
AT&T Global Network Client for Windows Product Support Matrix January 29, 2015 Product Support Matrix Following is the Product Support Matrix for the AT&T Global Network Client. See the AT&T Global Network
More informationPharmacogenomic Approaches. Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain
Pharmacogenomic Approaches Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain Pharmacogenetics & Pharmacogenomics Medicine tailored to the individual Genetic information, including the
More informationPET. Can we afford PET-CT. Positron annihilation. PET-CT scanner. PET detection
PET-CT Can we afford PET-CT John Buscombe New technology Combines functional information-pet anatomical information-ct Machine able to perform both studies in single imaging episode PET imaging depends
More informationGemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer
Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single
More informationThe Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma
The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma 11 th Annual National Leadership Summit on Health Disparities Innovation Towards Reducing Disparities Congressional Black
More informationScottish Medicines Consortium
Scottish Medicines Consortium pemetrexed 500mg infusion (Alimta ) No. (192/05) Eli Lilly 8 July 2005 The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS
More informationControversies in Management of. Inoperable NSCLC. Inoperable NSCLC. Introduction:
Inoperable NSCLC Controversies in Management of Inoperable NSCLC Introduction: It is difficult to overemphasize the magnitude of lung cancer as Public Health Problem in our society. - In US, Lung cancer
More informationCytoreduction and hyperthermic intraperitoneal chemotherapy for the treatment of pseudomyxoma
Medical Policy Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pseudomyxoma Peritonei and Peritoneal Carcinomatosis of Gastrointestinal Origin, and Peritoneal Mesothelioma
More informationManagement of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist
Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the
More informationSMALL CELL LUNG CANCER
Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New
More informationMore than half of all lung cancer patients present with. New Combinations in the Treatment of Lung Cancer* A Time for Optimism
New Combinations in the Treatment of Lung Cancer* A Time for Optimism Paul A. Bunn, Jr., MD; and Karen Kelly, MD Strides have been made in the treatment of lung cancer in the last decade that warrant a
More informationAvastin in Metastatic Breast Cancer
Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche
More informationCetuximab (Erbitux) MM.04.005 05/10/2005. HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s) of Service: Office: Outpatient
Cetuximab (Erbitux) Policy Number: Original Effective Date: MM.04.005 05/10/2005 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s)
More informationHER2 Status: What is the Difference Between Breast and Gastric Cancer?
Ask the Experts HER2 Status: What is the Difference Between Breast and Gastric Cancer? Bharat Jasani MBChB, PhD, FRCPath Marco Novelli MBChB, PhD, FRCPath Josef Rüschoff, MD Robert Y. Osamura, MD, FIAC
More informationCancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the
More informationManagement of Platinum-Sensitive Recurrent Ovarian Cancer
Management of Platinum-Sensitive Jacobus Pfisterer a and Jonathan A. Ledermann b The majority of patients with ovarian cancer will relapse despite state-of-the-art first-line surgery and chemotherapy.
More informationCOMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS*
COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) 2 Fixed Rates Variable Rates FIXED RATES OF THE PAST 25 YEARS AVERAGE RESIDENTIAL MORTGAGE LENDING RATE - 5 YEAR* (Per cent) Year Jan Feb Mar Apr May Jun
More informationCOMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS*
COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) 2 Fixed Rates Variable Rates FIXED RATES OF THE PAST 25 YEARS AVERAGE RESIDENTIAL MORTGAGE LENDING RATE - 5 YEAR* (Per cent) Year Jan Feb Mar Apr May Jun
More informationMetastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011
Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare
More informationActivity of pemetrexed in thoracic malignancies
Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is
More informationPancreatic Cancer: FDA Approved Treatments and Clinical Trials
Pancreatic Cancer: FDA Approved Treatments and Clinical Trials Vincent J Picozzi MD MMM Virginia Mason Medical Center Seattle WA 1 Pancreatic cancer is the hardest cancer of all to treat 2 Pancreatic cancer:
More informationSummary of treatment benefits
Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell
More informationNonanthracycline Containing Docetaxel-Based Combinations in Metastatic Breast Cancer
nanthracycline Containing Docetaxel-Based Combinations in Metastatic Breast Cancer JOHN CROWN St. Vincent s Hospital, Dublin, Ireland Key Words. MBC Docetaxel Cisplatin Carboplatin Vinorelbine Gemcitabine
More informationCome è cambiata la storia naturale della malattia
Malattia Metastatica del Carcinoma del Grosso Intestino Tecniche e terapie Innovative Come è cambiata la storia naturale della malattia Antonio Frassoldati Oncologia Clinica - Ferrara 29 ottobre 2011 Colorectal
More informationMEDICAL POLICY SUBJECT: PROSTATE CANCER SCREENING, DETECTION AND MONITORING
MEDICAL POLICY PAGE: 1 OF: 8 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationManagement of Peritoneal Metastases (PM) from colorectal cancers: New Perspectives. Dominique ELIAS
Management of Peritoneal Metastases (PM) from colorectal cancers: New Perspectives Dominique ELIAS Declaration of interest BOARDS Congress and teaching 0 Merck 0 Ipsen Novartis Sanofi Trials The peritoneum
More informationTargeting angiogenesis in NSCLC: Clinical trial update Martin Reck Lung Clinic Grosshansdorf Grosshansdorf, Germany
Targeting angiogenesis in NSCLC: Clinical trial update Martin Reck Lung Clinic Grosshansdorf Grosshansdorf, Germany This presentation was selected by the 15 th World Conference on Lung Cancer Program Committee
More informationMOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015
Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future
More informationIntegrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases
I Congresso de Oncologia D Or July 5-6, 2013 Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University
More informationMesothelioma 2014. Paul Baas Department of Thoracic Oncology The Netherlands Cancer Institute Amsterdam
Mesothelioma 2014 Paul Baas Department of Thoracic Oncology The Netherlands Cancer Institute Amsterdam Disclosures Grants from Pfizer and Roche Advisor for MSD and Verastem Once upon a time. http://amlbenzene.net/diseases-asbestos.htm
More informationthe standard of care 2009 5/1/2009 Mesothelioma: The standard of care take home messages PILC 2006 Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009
Mesothelioma: The standard of care Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009 take home messages PILC 2006 All patients should receive adequate palliation of dyspnea and pain before starting chemotherapy
More informationMedication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010
Medication Policy Manual Policy No: dru213 Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Committee Approval Date: February 17, 2015 Next Review Date: February 2016 Effective Date: March 1, 2015
More informationNew developments and controversies in breast cancer treatment: PARP Inhibitors: a breakthrough?
New developments and controversies in breast cancer treatment: PARP Inhibitors: a breakthrough? F. Cardoso, MD Champalimaud Cancer Center Lisbon, Portugal BBM 2010 Thank you to A Tutt & PRIME Oncology
More informationLung Cancer: More than meets the eye
Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research
More informationStage IV Renal Cell Carcinoma. Changing Management in A Comprehensive Community Cancer Center. Susquehanna Health Cancer Center
Stage IV Renal Cell Carcinoma Changing Management in A Comprehensive Community Cancer Center Susquehanna Health Cancer Center 2000 2009 Warren L. Robinson, MD, FACP January 27, 2014 Introduction 65,150
More informationPost-operative intrapleural chemotherapy for mesothelioma
Post-operative intrapleural chemotherapy for mesothelioma Robert Kratzke, MD John Skoglund Chair for Lung Cancer Research Section of Heme-Onc-Transplant University of Minnesota Medical School Efficacy
More informationHarmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART
Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART Goals Discuss treatment options for stage 4 lung cancer: New and old Discuss new developments in personalized
More informationSEARCH METHODOLOGY SEARCH STRATEGY #1 (SYSTEMATIC REVIEWS): PubMed 1966-3/16/2012 Cochrane Database of Systematic Reviews All years
Appendix A. Search Strategy for Systematic Reviews and Cost-Effectiveness Analyses (Search #1) TREATMENT OF METASTATIC NON-SMALL-CELL LUNG CANCER SEARCH METHODOLOGY SEARCH STRATEGY #1 (SYSTEMATIC REVIEWS):
More informationSmall Cell Lung Cancer
Small Cell Lung Cancer Types of Lung Cancer Non-small cell carcinoma (NSCC) (87%) Adenocarcinoma (38%) Squamous cell (20%) Large cell (5%) Small cell carcinoma (13%) Small cell lung cancer is virtually
More informationSAKK Lung Cancer Group. Current activities and future projects
SAKK Lung Cancer Group Current activities and future projects SAKK Lung Cancer Group Open group of physicians interested in lung cancer Mostly Medical Oncologists, but also Thoracic Surgeons Radiation
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT
More informationOI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ
OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase
More informationEverolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line
More informationTreatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
Department of Veterans Affairs Health Services Research & Development Service Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
More informationSECOND-LINE CHEMOTHERAPY in advanced non
Gemcitabine as Second-Line Treatment for Advanced Non Small-Cell Lung Cancer: A Phase II Trial By Lucio Crinò, Anna Maria Mosconi, Giorgio Scagliotti, Giovanni Selvaggi, Silvia Novello, Massimo Rinaldi,
More informationAppendix One. HER2-positive early breast cancer, its treatment and prognosis
Appendix One. HER2-positive early breast cancer, its treatment and prognosis Breast cancer and HER2/neu over-expression Health need is one of PHARMAC s nine decision criteria (http://www.pharmac.govt.nz/pdf/231205.pdf
More informationApproccio multidisciplinare nel carcinoma della vescica. D. Amoroso Dip. di Oncologia Medica Ospedale Versilia Lido di Camaiore (LU)
Approccio multidisciplinare nel carcinoma della vescica D. Amoroso Dip. di Oncologia Medica Ospedale Versilia Lido di Camaiore (LU) Disclosures Advisory Role, Honoraria: ü Roche ü Italfarmaco Outline v
More informationMolecular markers and clinical trial design parallels between oncology and rare diseases?
Molecular markers and clinical trial design parallels between oncology and rare diseases?, Harriet Sommer Institute for Medical Biometry and Statistics, University of Freiburg Medical Center 6. Forum Patientennahe
More informationGUIDELINES ADJUVANT SYSTEMIC BREAST CANCER
GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER Author: Dr Susan O Reilly On behalf of the Breast CNG Written: December 2008 Agreed at CNG: June 2009 & June 2010 Review due: June 2011 Guidelines Adjuvant Systemic
More informationRe irradiation Using HDR Interstitial Brachytherapy for Locally Recurrent. Disclosure
Re irradiation Using HDR Interstitial Brachytherapy for Locally Recurrent Cervical lcancer Yasuo Yoshioka, MD Department of Radiation Oncology Osaka University Graduate School of Medicine Osaka, Japan
More informationStage 3 Lung Cancer - Know YourSurviving Conditions
Survival of Stage IIIb and IV Non-Small Cell Lung Cancer Patients on Best Supportive Care in Manitoba, Canada Erich Kliewer Alain Demers Sri Navaratnam Coreen Hildebrand Grace Musto Report for AstraZeneca
More informationChemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group
Chemotherapy in Ovarian Cancer Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Adjuvant chemotherapy for early stage EOC Fewer than 30% women present with FIGO stage
More informationLONDON CANCER NEWS DRUGS GROUP RAPID REVIEW. FOLFIRINOX for first line treatment of advanced pancreatic cancer January 2012
Background LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW FOLFIRINOX for first line treatment of advanced pancreatic cancer January 2012 The incidence of pancreatic cancer in the UK is 9.4/100,000. It is
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationNon-Small Cell Lung Cancer
Non-Small Cell Lung Cancer in East tasia Chia-Chi (Josh) Lin, MD, PhD 林 家 齊 Director of Phase I Center, e Department of Oncology, National Taiwan University Hospital Clinical Associate Professor, Department
More informationChemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen.
Chemotherapy in Luminal Breast Cancer: Choice of Regimen Andrew D. Seidman, MD Attending Physician Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell
More informationAdvances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG 99-16 study results presented at ASCO 2004
Ronald de Wit Rotterdam Cancer Institute The Netherlands Advances In Chemotherapy For Hormone Refractory Prostate Cancer TAX 327 study results & SWOG 99-16 study results presented at Slide 1 Prostate Cancer
More informationTargeted therapies and brain metastases in lung cancer patients. Benjamin Besse, MD, PhD. Medical Oncologist. 19 septembre 2014
Targeted therapies and brain metastases in lung cancer patients Benjamin Besse, MD, PhD Medical Oncologist 19 septembre 2014 Targeted therapies and brain mets! Brain mets in NSCLC! Specific targeted therapies!
More informationLondon Cancer. Mesothelioma Lung Protocols
London Cancer Mesothelioma Lung Protocols Version 0.9 Contents 1. Staging... 3 2. Mesothelioma Summary of Chemotherapy Protocols... 4 3. Mesothelioma Chemotherapy Protocols... 7 3.1. Pemetrexed (Alimta
More informationTreatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
Department of Veterans Affairs Health Services Research & Development Service Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
More informationEndpoints and quality of life
Endpoints and quality of life PFS, OS, quality of life and medico-economic assessment in oncology Isabelle Durand-Zaleski, Jérôme Garnier, Mira Pavlovic, and participants of roundtable n 3 Pascal Bilbault,
More informationKanıt: Klinik çalışmalarda ZYTIGA
mkdpk de Sonunda Gerçek İlerleme! Kanıt: Klinik çalışmalarda ZYTIGA Dr. Sevil Bavbek 5. Türk Tıbbi Onkoloji Kongresi Mart 214, Antalya Endocrine therapies Adrenals Testis Abiraterone Orteronel Androgen
More informationStomach (Gastric) Cancer. Prof. M K Mahajan ACDT & RC Bathinda
Stomach (Gastric) Cancer Prof. M K Mahajan ACDT & RC Bathinda Gastric Cancer Role of Radiation Layers of the Stomach Mucosa Submucosa Muscularis Serosa Stomach and Regional Lymph Nodes Stomach and Regional
More informationThird-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status
Available online at www.sciencedirect.com Journal of the Chinese Medical Association 74 (2011) 209e214 Original Article Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with
More informationShifting the Paradigm for Maintenance Therapy for Non small-cell Lung Cancer
J Hong Kong Col Radiol. 2010;13(Suppl):S16-21 ORIGINAL ARTICLE Shifting the Paradigm for Maintenance Therapy for Non small-cell Lung Cancer VHF Lee Department of Clinical Oncology, Queen Mary Hospital,
More informationwith ovarian cancer exhibit an initial response. 5 In addition, the majority of
Research ONCOLOGY Impact of a chemoresponse assay on treatment costs for recurrent ovarian cancer Laura J. Havrilesky, MD, MHSc; Thomas C. Krivak, MD; John W. Mucenski, PharmD; Evan R. Myers, MD, MPH OBJECTIVE:
More informationNon-Small Cell Lung Cancer
Non-Small Cell Lung Cancer John delcharco, MD (Statistics based on CVMC data 2009-2013) Statistics Lung cancer is the leading cause of cancer deaths in the United States. The American Cancer Society estimates
More informationHow TARGIT Intra-operative Radiotherapy can help Older Patients with Breast cancer
How TARGIT Intra-operative Radiotherapy can help Older Patients with Breast cancer Jeffrey S Tobias, Jayant S Vaidya, Frederik Wenz and Michael Baum, University College Hospital, London, UK - on behalf
More informationRecent Trends in Management of Unresectable Non-Small Cell Lung Cancer (NSCLC)
Bahrain Medical Bulletin, Vol.23, No.4, December 2001 Recent Trends in Management of Unresectable Non-Small Cell Lung Cancer (NSCLC) Jalal Al-Maskati, MBChB, ABIM * Lung cancer is a major health problem
More informationCHEMOTHERAPY FOR ADVANCED UROTHELIAL CANCER OF THE BLADDER. Walter Stadler, MD University of Chicago
CHEMOTHERAPY FOR ADVANCED UROTHELIAL CANCER OF THE BLADDER Walter Stadler, MD University of Chicago Chemotherapy Doctor Terms Drugs used to treat cancer Will attack cancer no matter where it is located
More informationCase 2:08-cv-02463-ABC-E Document 1-4 Filed 04/15/2008 Page 1 of 138. Exhibit 8
Case 2:08-cv-02463-ABC-E Document 1-4 Filed 04/15/2008 Page 1 of 138 Exhibit 8 Case 2:08-cv-02463-ABC-E Document 1-4 Filed 04/15/2008 Page 2 of 138 Domain Name: CELLULARVERISON.COM Updated Date: 12-dec-2007
More informationNATIONAL CANCER DRUG FUND PRIORITISATION SCORES
NATIONAL CANCER DRUG FUND PRIORITISATION SCORES Drug Indication Regimen (where appropriate) BORTEZOMIB In combination with dexamethasone (VD), or with dexamethasone and thalidomide (VTD), is indicated
More informationSmall Cell Lung Cancer
Small Cell Lung Cancer Lung Practice Guideline Dr. Brian Dingle MSc, MD, FRCPC Approval Date: April 2007 Revised: November 2008 This guideline is a statement of consensus of the Thoracic Disease Site Team
More informationUpdate on Small Cell Lung Cancer
Welcome to Master Class for Oncologists Session 3: 2:45 PM - 3:30 PM Washington, DC March 28, 2009 Small Cell Lung Cancer: Best Practices & Recent Advances Speaker: Bruce E. Johnson, MD Professor of Medicine,
More informationGuideline Development The American Society of Clinical Oncology
Assessing Genomic Sequencing Information for Health Care Decision Making Decision Making Once Evidence is Assessed/Graded Evaluated Guideline Development The American Society of Clinical Oncology Gary
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More information